Topics on MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease)

Abstract

 In 2023, the term "non-alcoholic fatty liver disease" was changed to "metabolic dysfunction-associated steatotic liver disease" (MASLD) to emphasize the significance of metabolic disease and include moderate alcohol consumption within its classification. The prognosis of MASLD encompasses both liver-related and cerebrovascular and cardiovascular events, as well as cancers in organs other than the liver. The progression of liver fibrosis in patients with MASLD is associated with diabetes and the presence of risk alleles in the patatin-like phospholipase domain-containing 3 gene. Noninvasive diagnostic methods are investigated to diagnose fibrosis, in order to provide alternatives to liver biopsy. The cornerstone of MASLD treatment is diet and exercise therapy, with no currently approved drugs covered by insurance. Several clinical trials are ongoing for the development of new medications.